Horm Metab Res 2007; 39(5): 395-397
DOI: 10.1055/s-2007-977694
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

Genetic Variation in Two Proteins of the Endocannabinoid System and their Influence on Body Mass Index and Metabolism under Low Fat Diet

J. Aberle 1 , I. Fedderwitz 1 , N. Klages 1 , E. George 1 , F. U. Beil 1
  • 1Zentrum für Innere Medizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Further Information

Publication History

received 26. 10. 2006

accepted 8. 1. 2007

Publication Date:
29 May 2007 (online)

Abstract

The endocannabinoid system (ECS) plays an important and not yet fully understood role in hypothalamic and peripheral regulation of food intake, obesity, and metabolism. Two frequent single nucleotide polymorphisms (snp) have been identified in members of the ECS: the 1359 G/A variant in the cannabinoid receptor 1 (CB1) and the P129T polymorphism in fatty acid amide hydrolase (FAAH), a key degradation enzyme of endocannabinoids. -While for the 1359 G/A variant an association has been shown only with psychiatric diseases such as drug-abusing schizophrenia, the P129T polymorphism has recently been proved to be correlated to a higher body mass index (BMI) in a group of black and white Americans. However, no knowledge exists as to whether these variants affect the outcome of a low fat diet in obese subjects. Therefore, we genotyped a group of 451 obese and dyslipidaemic participants and observed the biometric and metabolic outcome of a 6 week low fat diet. While no significance was seen for the 1359 G/A variant, carriers of the P129T mutation in FAAH had a significantly greater decrease in triglycerides and total cholesterol as compared to wild type. The reason for our findings remains to be elucidated, however, a hepatic downregulation of endocannabinoid tone may contribute to the observed outcome in studied subjects.

References

  • 1 Matsuda LA, Lolait SH, Brownstein MJ, Yound AC, Bonner TI. Nature. 1990;  346 561-564
  • 2 Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst ACE, Pasquali R, Lutz B, Stalla GK, Pagotto U. J Clin Invest. 2003;  112 423-431
  • 3 Kirkham TC, Williams CM, Fezza F, Di Marzo V. Br J Pharmacol. 2002;  136 550-557
  • 4 Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Nature. 2001;  410 822-825
  • 5 Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G. J Clin Investig. 2005;  115 1298-1305
  • 6 Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V. JCEM. 2006;  91 3171-3180
  • 7 Shook JE, Burks TF. J Pharmacol Exp Ther. 1999;  249 444-449
  • 8 Liu YL, Connoley IP, Wilson CA, Stock MJ. Int J Obes. 2005;  29 183-187
  • 9 Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd A, Bukoski RD, Kunos G. Circulation. 2004;  110 1996-2002
  • 10 Perwitz N, Fasshauer M, Klein J. Horm Metab Res. 2006;  38 356-358
  • 11 Gadzicki D, Müller-Vahl KR, Stuhrmann M. Mol Cell Probes. 1999;  13 321-323
  • 12 Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO. Am J Med Gen. 2001;  105 749-752
  • 13 Sipe JC, Waalen J, Gerber A, Beuter E. Int J Obes. 2005;  20 755-759
  • 14 Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. Proc Natl Acad Sci USA. 2002;  99 8394-8399
  • 15 Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Lancet. 2005;  365 1389-1397
  • 16 Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Proc Natl Acad Sci USA. 2000;  97 6402-6406

Correspondence

J. Aberle

Zentrum für Innere Medizin

3. Medizinische Klinik

Universitätsklinikum

Hamburg-Eppendorf

Martinistr. 52

20246 Hamburg

Germany

Phone: +49/40/428 03 44 49

Fax: +49/40/428 03 23 17

Email: aberle@uke.uni-hamburg.de